ALNYLAM PHARMACEUTICALS, INC. Quarterly Interest Expense in USD from Q2 2019 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of the cost of borrowed funds accounted for as interest expense.
Summary
Alnylam Pharmaceuticals, Inc. quarterly/annual Interest Expense history and growth rate from Q2 2019 to Q1 2024.
  • Alnylam Pharmaceuticals, Inc. Interest Expense for the quarter ending March 31, 2024 was $35.3M, a 21.8% increase year-over-year.
  • Alnylam Pharmaceuticals, Inc. Interest Expense for the twelve months ending March 31, 2024 was $128M, a 10.6% decline year-over-year.
  • Alnylam Pharmaceuticals, Inc. annual Interest Expense for 2023 was $121M, a 22.3% decline from 2022.
  • Alnylam Pharmaceuticals, Inc. annual Interest Expense for 2022 was $156M, a 9.05% increase from 2021.
  • Alnylam Pharmaceuticals, Inc. annual Interest Expense for 2021 was $143M, a 69.3% increase from 2020.
Interest Expense, Trailing 12 Months (USD)
Interest Expense, Quarterly (USD)
Interest Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $128M $35.3M +$6.3M +21.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $121M $31.3M +$1.43M +4.76% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-15
Q3 2023 $120M $30.9M -$10.2M -24.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $130M $30M -$12.6M -29.5% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-03
Q1 2023 $143M $29M -$13.4M -31.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $156M $29.9M -$6.9M -18.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-15
Q3 2022 $163M $41.1M +$810K +2.01% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $162M $42.6M +$9.19M +27.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $153M $42.4M +$9.85M +30.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $143M $36.8M +$8.3M +29.1% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-15
Q3 2021 $135M $40.3M +$11.5M +40.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-27
Q2 2021 $123M $33.4M +$6.17M +22.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-28
Q1 2021 $117M $32.5M +$32.5M Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-28
Q4 2020 $84.5M $28.5M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-23
Q3 2020 $28.7M +$28.7M Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-28
Q2 2020 $27.2M +$27.2M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $0 Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-29
Q3 2019 $0 Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $0 Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.